Navigation Links
Ace Biosciences, Ace393, the World's First Commercial Vaccine for,Travellers' Diarrhoea Caused by Campylobacter Successfully,Completes Phase I Clinical Trials

Ace Biosciences, Ace393, the World's First Commercial Vaccine for Travellers' Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials

Trial confirms good safety profile and strong immunogenicity

ODENSE, Denmark, March 28, 2007 -ACE BioSciences A/S, the infectious diseases company is pleased to announce the successful completion of Phase I clinical trials with its lead product, ACE393, the world's first commercial vaccine for Travellers' Diarrhoea (TD) caused by Campylobacter infection.

ACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world. The two stage, double blind, randomised, placebo-controlled trial confirmed that the vaccine was very well tolerated and that the strongest immune response was stimulated by the highest dose when administered in two doses either two or three weeks apart, with 100% of subjects responding. Adverse reactions were transient local site reaction and headaches in some subjects.

Dr Philippe Reboud, (Mediscis Phase I clinical unit) the study_s Principal Investigator commented "These are very satisfying results. The study clearly confirms the vaccine's safety and tolerability. Furthermore, at the 250µg dose, ACE393 stimulates a four fold increase in IgG antibody titre in all subjects, indicating strong immunogenicity (ability to stimulate an immune response). In the past it has proved too challenging to develop an effective vaccine against Campylobacter infection and Travellers' Diarrhoea has been difficult to prevent, leading to the incidence of serious long-term post infection complications such as Guillain Barre Syndrome and reactive arthritis in a few patients. However, thanks to the innovative approach taken by ACE BioSciences, this looks set to change."

Ms Ingelise Saunders, ACE BioSciences, C
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
6. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
9. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
10. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
11. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica US ... leading online community to help oncologists and other clinicians ... regarding the use of targeted therapies and immunotherapies, discusses ... and treatment.  Every September, Blood ... to raise awareness about blood cancers—helping to increase survival ...
(Date:9/19/2014)...  Alere Inc. (NYSE: ALR ), a ... today in support of President Barack Obama,s ... global leader in rapid diagnostics for infectious disease, we ... address the serious threat of antibiotic resistance. We look ... initiatives to promote the development of rapid point-of-care tests ...
(Date:9/19/2014)... and ORLANDO, Fla. , Sept. ... Inspire therapy continues to grow, with the publication of ... on-line in Otolaryngology – Head and Neck ... a worsening of both objective and subjective measures of ... attribute Inspire therapy for the reduction in obstructive sleep ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4
... Scientific Resources, Inc. (OTCQB: ASFX) ("American Scientific Resources" ... Products) Ltd. ("Syner-Med") is the Company,s new distributor ... for its non-contact thermometers. Syner-Med placed an initial ... retail and professional models, of the VeraTemp non-contact ...
... LIVINGSTON, N.J., March 14 , 2011 Milestone ... develops, manufactures, and markets computer-controlled injection systems for medical ... has commenced trading on the OTCQB(TM) electronic quotation and ... not required to take any action as a result ...
Cached Medicine Technology:American Scientific Resources Announces New Distributor Syner-Med Placing Kidz-Med VeraTemp in the United Kingdom and Ireland 2American Scientific Resources Announces New Distributor Syner-Med Placing Kidz-Med VeraTemp in the United Kingdom and Ireland 3Milestone Scientific Inc. Commences Trading on the OTC Pink 2
(Date:9/19/2014)... (PRWEB) September 19, 2014 "I have ... getting wrinkles due to stretching the skin around my ... Ala. "This inspired me to design a more convenient ... CONTACT LENS SYSTEM provides a quicker, easier, more sanitary ... need to perform this task manually, saves time and ...
(Date:9/19/2014)... 2014 -- Recent two-generation approaches to reducing poverty ... increasing attention from researchers, advocates, and foundations. By ... them to move to jobs that offer a ... and education for children, these programs aim to ... according to a new report from the National ...
(Date:9/19/2014)... (HealthDay News) -- When it comes to firearm deaths, ... States, while the District of Columbia has the highest, ... deaths from gun-related violence -- including murders, suicides and ... the study revealed. Hawaii,s rate was roughly three per ... the District of Columbia had the highest rate of ...
(Date:9/19/2014)... Medical College of Wisconsin (MCW) scientists has identified a new ... mice and in humans. The findings are published in the ... Leah Solberg Woods, Ph.D., associate professor of pediatrics at MCW ... Institute, led the study and is the corresponding author of ... gene called Tpcn2 in which a variant was associated with ...
(Date:9/19/2014)... Top10BestSEOHosting.com today compares many professional Windows web hosting ... are the best suppliers of 2014. Clients who ... VPS and cloud hosting) at affordable rates can ... HostMonster ( http://www.hostmonster.com/track/seohosts ) helps business companies and ... the cost. As a top rated hosting provider, ...
Breaking Medicine News(10 mins):Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2Health News:Top10BestSEOHosting.com: They Are Best Windows Web Hosting Suppliers Of 2014 2
... use trends , , TUESDAY, March 4 (HealthDay News) -- When ... to give up the habit if it isn,t considered cool, ... research shows. , The findings will give prevention researchers ... embrace of illegal drugs, said study author Michelle Little, a ...
... to Take Action Against This Leading ... Cause of Home-Related Deaths, WASHINGTON, ... poisoning is the second leading,cause of home injury death in the ... one percent of U.S. adults ranked poisoning at the,top of the ...
... Estate Developer,s Foundation to Lead the ... in Ending Global Hunger, Improving Nutrition, NEW YORK, ... pledged a $15 million challenge grant to transform The ... Sciences in Rehovot, Israel. The gift will be the ...
... received a five-year, $20.5 million grant from the Bill ... investigating the biological factors underlying immune system control of ... provides support to the International HIV Controllers Study, which ... and has the overall goal of discovering information that ...
... Award and Massachusetts again takes ... top e-Prescribing State Honors, ... the leader in hosted services for email encryption and,e-prescribing, today ... 2008, for building awareness of improving,patient safety at the local ...
... AUSTIN, TX and TORONTO, March 4 /PRNewswire/ - ... dosing of healthy subjects in,a Phase I study ... from its,novel class of fatty acid biosyntheis inhibitors. ... and pharmacokinetics of a single,escalating oral dose. Affinium ...
Cached Medicine News:Health News:Troubled Boys Will Abandon Pot When It's Deemed Uncool 2Health News:New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home 2Health News:New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home 3Health News:New Home Safety Council(R) Research Shows the Majority of Families Underestimate the Danger of Poisoning Exposure at Home 4Health News:Robert H. Smith 'Feeding the Future' with $15 Million Gift to Hebrew University of Jerusalem 2Health News:Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study 2Health News:Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study 3Health News:Zix Corporation Celebrates National Patient Safety Awareness Week with Continued Success in e-Prescribing 2Health News:Zix Corporation Celebrates National Patient Safety Awareness Week with Continued Success in e-Prescribing 3Health News:Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic 2